tirzepatide head to head semaglutide tops for patient weight loss, study finds First head-to-head trial compares tirzepatide

An ongoing phase 3 trial, the SELECT study, will evaluate the cardiovascular benefit of semaglutide beyond blood glucose control, as the study population is composed of individuals who are overweight or obese without diabetes [81]

Many people feel less supported or accountable without regular medication and appointments

Study on pharmacological effects of cultivated bezoar and natural bezoar

Stay on track. Doctor-guided treatment for $39 for your first month of membership + cost of medication.* $39 promotional rate available for new subscribers only

SGLT2 inhibitors block the reabsorption of glucose in the kidney, increase glucose excretion, and lower blood glucose levels